金福安汤联合化疗治疗非小细胞肺癌的效果及对患者血清癌胚抗原、骨胶素水平的影响

The effects of the Jinfu’an decoction plus chemotherapy on non-small cell lung cancer and its effect on serum CEA and CY211 levels in patients

目的:探讨金福安汤联合化疗治疗非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)的效果。方法:选取2019年1—10月来我院就诊的129例NSCLC患者为研究对象,使用随机简单化法将其分为联合组(65例)和常规组(64例),常规组予合紫杉醇联合顺铂(TP)方案治疗,联合组在常规组的基础上予以金福安汤治疗。观察两组患者治疗后临床效果,中医证候积分、癌胚抗原(Carcinoembryonic Antigen,CEA)、骨胶素(CY211)水平及不良反应。结果:治疗后联合组总有效率高于常规组(P<0.05),中医证候积分低于常规组(P<0.05),CEA、CY211水平低于常规组(P<0.05),不良反应发生率低于常规组(P<0.05)。结论:金福安汤联合化疗治疗NSCLC能有效提高临床治疗效果,降低中医证候积分、CEA水平、CY211水平及不良反应。

Objective:To explore the effects of the Jinfu’an decoction(金福安汤)plus chemotherapy on Non-small Cell Lung Cancer(NSCLC).Methods:129 cases were divided into the combined group(65 cases)and the routine group(64 cases).The routine group was treated with paclitaxel plus cisplatin(TP)regimen,and the combined group received the Jinfu’an decoction more.Results:The total efficiency in the combined group was higher than the routine group(P<0.05).The TCM syndrome score,CEA and CY211 levels,and adverse reactions in the combined group were lower(P<0.05).Conclusion:The Jinfu’an decoction plus chemotherapy on NSCLC can effectively improve the clinical effect,and reduce the TCM syndrome score,CEA level,CY211 level and the incidence of adverse reactions.